酸治疗逆转了急性心肌梗塞的子的大动脉内皮功能障碍
Sol Guerra-Ojeda1, Andrea Suarez1, Begoña Belmonte1
1Department of Physiology. School of Medicine, University of Valencia, Spain; Institute of Health Research INCLIVA, Valencia, Spain.
European journal of pharmacology
|March 4, 2024
概括
甲 (VPA) 通过抗氧化作用增加氧化 (NO) 的生物可用性,从而逆转急性心肌梗塞 (AMI) 中的内皮功能障碍,这表明VPA是潜在的再输液疗法.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 急性心肌梗塞 (AMI) 通常导致内皮功能障碍,损害血管健康.
- 激素脱乙酶 (HDAC) 抑制剂,如甲 (VPA),正在研究心血管疾病的治疗潜力.
研究的目的:
- 研究甲 (VPA) 对由急性心肌梗塞 (AMI) 引起的内皮功能障碍的治疗作用.
- 在实验性AMI模型中阐明VPA作用的潜在机制.
主要方法:
- 在子中通过冠状动脉封闭和再注血诱导AMI.
- 动物接受了VPA (500毫克/公斤/天) 或假操作的治疗.
- 通过同度张力记录来评估血管功能;测量蛋白质表达 (SOD 1) 和NOx水平.
主要成果:
- AMI诱导了显著的内皮功能障碍,以减少对乙胆的反应为证据.
- VPA治疗恢复了内皮依赖的血管扩张,并增强了血管光滑肌肉对氧化 (NO) 的敏感性.
- VPA逆转了AMI诱导的超氧化失调酶1 (SOD1) 的下调,表明它具有抗氧化作用.
结论:
- 甲 (VPA) 通过增强NO的生物可用性,主要通过其抗氧化特性,改善AMI中的血管扩张.
- 由于VPA能够抵消内皮功能障碍,使其成为AMI中转流疗法的有希望的候选人,以防止血管损伤.
相关概念视频
Aortic Regurgitation III: Medical Management
598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753


